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A B S T R A C T
Aspergillus can cause a wide variety of diseases ranging from hypersensitivity diseases to invasive infection.
Invasive disease most commonly occurs in severely immunocompromised patients such as chemotherapy-in-
duced neutropenia and transplantation. It is a less well-recognized complication in critically ill patients without
traditional risk factors. We describe a case of invasive aspergillosis complicating inﬂuenza and diabetic ketoa-
cidosis that disseminated to the central nervous system and led to demise despite high-intensity antifungal
therapy.
1. Introduction
Aspergillus is a common soil and environmental fungus that can
cause a variety of diﬀerent diseases in both immunocompromised and
immunocompetent hosts. Invasive aspergillosis, which is the most
dreaded form of the disease, typically occurs in individuals with pro-
found immunosuppression such as hematopoietic stem cell transplant,
solid organ transplant, chemotherapy-induced neutropenia, and sig-
niﬁcant corticosteroid exposure [1]. A less common but well-re-
cognized risk factor for invasive pulmonary aspergillosis (IPA) is critical
illness requiring mechanical ventilation. It is estimated that the in-
cidence of IPA in the ICU population may be as high as 7%, where
patients commonly have multiple risk factors including acute re-
spiratory failure, mechanical ventilation, steroid use, acute renal failure
and comorbid illness [2]. Invasive aspergillosis most commonly pre-
sents as sinopulmonary disease due to inhalation of spores. From the
lungs, Aspergillus may disseminate hematogenously to the skin, bone,
visceral organs and the central nervous system.
Other presentations of Aspergillus disease primarily depend on the
pulmonary structure or underlying disease of the patient. In patients
who have a pre-existing cavitary lesion in their lungs, Aspergillus can
sometimes colonize that space and form an Aspergilloma or fungus ball.
This may be the most common disease caused by Aspergillus species,
although fungus balls can sometimes be caused by other fungi as well.
Aspergilloma is a limited disease and typically does not invade into the
lung parenchyma or blood vessels [3]. Aspergilloma can be seen on
computed tomography and conﬁrmed by culture or histological iden-
tiﬁcation of Aspergillus in sputum, bronchoalveolar lavage ﬂuid, or
trans-thoracic needle aspirations [4]. Another disease entity caused by
Aspergillus is Allergic Bronchopulmonary Aspergillosis (ABPA), which
is a hypersensitivity reaction, with the majority of cases in those with
cystic ﬁbrosis or asthma, especially those who are corticosteroid-de-
pendent [3]. ABPA may manifest as developing chronic and inter-
mittent lung inﬂammation sometimes leading to bronchiectasis. Diag-
nosis is clinical and requires a number of criteria to make ABPA likely:
asthma, peripheral eosinophilia, skin test reactivity to Aspergillus,
precipitating IgG antibodies to Aspergillus, and elevated serum IgE [4].
Aspergillus may also present in a number of overlapping chronic
manifestations. Chronic disease almost always occurs in the setting of
previous structural lung disease and manifestations are probably
modulated by varying and ongoing immunosuppression. Under the
umbrella of chronic pulmonary aspergillosis (CPA), there are a couple
of entities of note. In those with some degree of immunosuppression
(chronic corticosteroid-use, AIDS, diabetes mellitus, alcoholism) pa-
tients may develop a more rapidly evolving form of disease called
chronic necrotizing pulmonary aspergillosis (CNPA) characterized by
the formation of nodules, consolidations with or without the develop-
ment of cavities in the lungs. A less destructive and slowly evolving
form of disease characterized by single or multiple cavities with thick
walls is called chronic cavitary pulmonary aspergillosis (CCPA). In
some patients with CCPA who develop extensive ﬁbrosis, they may be
classiﬁed as chronic ﬁbrosing pulmonary aspergillosis [1]. Isolated
tracheobronchial disease is a rare subtype of Aspergillus and may be
diagnosed as a bronchial plaque and can present with or without par-
enchymal disease [1].
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2. Case
A 38-year-old woman with uncontrolled type 2 diabetes presented
to the emergency room with 1 week of chills, fever, nausea, vomiting,
cough and sore throat. In the emergency room, her initial exam de-
monstrated bilateral rales as well as mild distress. Skin, abdominal, and
cardiac exams were normal. Her initial vital signs showed that she was
afebrile, tachycardic to the 130s, tachypneic with a respiratory rate of
37, and O2 saturation of 98% on room air. Her initial work-up was
signiﬁcant for WBCs of 11,600/mm3 and glucose of 776 mg/dL with an
anion gap of 20. On venous blood gas pH was 6.84 and HCO3 of
4mmHg. Her initial chest x-ray showed a right middle and left lower
lobe consolidation compatible with pneumonia (Fig. 1).
She developed respiratory distress and altered mental status while
undergoing evaluation in the ED and required intubation and admission
to the ICU for acute respiratory failure, septic shock, and diabetic ke-
toacidosis. She was started on broad-spectrum antibacterials as well as
oseltamivir. A nasopharyngeal swab was positive for inﬂuenza B and
blood cultures were positive for Streptococcus pneumoniae. A broncho-
scopy performed 14 hours after admission demonstrated many Gram-
positive cocci in pairs and whitish plaques in the tracheobronchial tree
which were overlooked. BAL cultures conﬁrmed Streptococcus pneumo-
niae infection. On hospital day 4 due to continued alteration in mental
status and persistent fevers and leukocytosis she underwent Head CT
and LP which were unremarkable. Due to lack of clinical improvement
she underwent CT chest on hospital day 6 demonstrating multifocal
nodular consolidations with early cavitation (Fig. 2).
On hospital day 9 Aspergillus fumigatus was ﬁnally identiﬁed on her
admission BAL. She was immediately started on voriconazole. Further
diagnostic evaluation included serum Fungitell ((1–3)-ß-D-Glucan) and
Aspergillus antigen which were strongly positive. Repeat bronchoscopy
showed a whitish collection of material in the left main bronchus
(Fig. 3) which was biopsied and revealed abundant fungal hyphae on
pathology consistent with Aspergillus.
On hospital day 11 a repeat CT chest showed new large areas of
cavitation bilaterally with some surrounding groundglass halos, mostly
at sites of previous consolidations (Fig. 4).
Due to worsening cavitary disease on imaging and the burden of
infection micafungin was added on hospital day 12. On hospital day 13
an MRI brain with and without contrast was ordered due to the patient's
continued lack of neurological improvement which showed multifocal
area of prominent T2 hyperintensity in both frontal lobes and left
thalamus suggestive of CNS aspergillosis. Due to the presence of tra-
cheobronchial aspergillosis and evidence of endobronchial spread on
imaging, nebulized amphotericin B was added.
On hospital day 15, bronchoscopy showed exudate throughout the
tracheobronchial tree. Cryotherapy was performed in the left upper
lobe for debulking of fungal burden. For ﬁve more days she was con-
tinued on high-intensity antifungal treatment without neurological
improvement. On HD 20 amphotericin B was switched from nebulized
to intravenous. A repeat MRI brain on HD 20 showed unresolved lesions
in the frontal lobe and some scattered 5mm foci in the left corona ra-
diata while showing a smaller yet still present thalamic lesion (Fig. 5).
The patient was kept on her treatment but did not have further clinical
improvement. After some additional radiographic evidence of bony
involvement in some of her ribs, and due to a lack of response despite
antifungal treatment, she was diagnosed with overwhelming dis-
seminated aspergillosis and her family agreed to withdraw care. On HD
25 she was extubated and expired the same day.
3. Discussion
There is growing recognition of invasive pulmonary aspergillosis
complicating severe inﬂuenza infections since the H1N1 2009 epidemic
[5]. One proposed mechanism for how inﬂuenza puts the lungs at in-
creased risk of invasive aspergillosis is pathological evidence for the
virus causing diﬀuse alveolar damage, necrosis of bronchial mucosa,
and submucosal hemorrhage. Inﬂuenza viruses and strains infect the
epithelium from the nasal passage to the bronchioles, and some high
virulence strains may cause more diﬀuse damage. This damage to
epithelium is why classically one may see post-inﬂuenza bacterial
pneumonia [6] as seen in this case report. Another theory for post-in-
ﬂuenza infections is a systemic viral-induced Th1/Th2 changes and
lymphopenia which puts patients at risk for secondary bacterial and
occasional fungal infection [7]. Since the immune control of Aspergillus
is dependent on T-cell immunity, the viral-induced lymphopenia caused
by an inﬂuenza infection may be the key to increased risk for secondary
aspergillus infections [8]. This damage may also disrupt the epithelium
and allow for fungal hyphae invasion and hematogenous spread in se-
vere cases. Invasive Aspergillus infections are more commonly asso-
ciated with inﬂuenza A, although a smaller number cases in the lit-
erature are associated with inﬂuenza B, which can also cause ciliary
stripping and focal necrosis and hemorrhage in the upper respiratory
tract [9].
Fig. 1. Chest x-ray on hospital day 1 showing right middle and left lower lobe
consolidation.
Fig. 2. CT Chest on HD 5 showing multifocal nodular consolidations with early
cavitation (red arrow).
Fig. 3. Bronchoscopy on HD 9 showing white fungus ball in left main bronchus.
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In this case report, the patient had a superimposed pneumococcal
pneumonia complicating her inﬂuenza, which made detection of
Aspergillus challenging. The inﬂuenza infection could have made her
more susceptible to both secondary infections, but the bacterial one was
discovered and treated ﬁrst, while the fungal infection was not dis-
covered until much later in her hospital course. Since clinical and
radiological manifestations of aspergillosis may be non-speciﬁc, it is
critical that there is prompt recognition of this fungal infection so an-
tifungal therapy can be initiated early [4]. Based on reported cases,
invasive aspergillosis complicating inﬂuenza appears to occur early
with the median time of 5–6 days between admission and diagnosis of
aspergillosis [5,7].
Another peculiar aspect of this case was that the patient presented
on admission with evidence of fungal disease, as the initial broncho-
scopy eventually grew Aspergillus. Intensive care and intubation are
associated with invasive Aspergillus infections, with patients devel-
oping disease after multiple days already in the ICU suggesting noso-
comial acquisition [2,10]. This patient was intubated in the ED and
transferred to the ICU and was not diagnosed with Aspergillus until
hospital day 9, but she had evidence of the disease upon admission
consistent with community-acquired infection. Notably, she presented
with tracheobronchial involvement with bronchial plaques noted on
her admission bronchoscopy. Invasive tracheobronchial aspergillosis is
a rare sub-type of invasive aspergillosis limited to the tracheobronchial
tree and makes up only about 7% of pulmonary cases and can present as
ulcerative or pseudomembranous forms [14]. It is usually seen in se-
verely immunocompromised patients and in those who have received a
lung transplant. It has been proposed that Aspergillus tracheobronchitis
may also be occasionally present in more mildly immunocompromised
patients such as the elderly, patients with COPD, post-inﬂuenza, or
uncontrolled diabetes [13].
Only one form of Aspergillus, Chronic Necrotizing Pulmonary
Aspergillosis (CNPA), has been associated with diabetes in the litera-
ture. CNPA can present with constitutional symptoms and dyspnea and
may appear radiologically indistinguishable from an aspergilloma.
While a simple aspergilloma has a thin-walled cyst, complex aspergil-
lomas may present with thick-walled cavities and parenchymal lung
inﬁltrates. CNPA may present as a complex aspergilloma that begins as
a small or ill-deﬁned area of consolidation that progresses to well-de-
ﬁned cavities. Expanding cavities and paracavitary invasion is typical
[11]. Patients with CNPA may manifest a more rapidly evolving disease
[1]. Additionally, diabetics are also known to have impaired host re-
sponses, which could indicate that uncontrolled diabetes is a non-tra-
ditional risk factor for invasive Aspergillus infections as well [13].
Cerebral dissemination has the worst prognosis of any of the many
manifestations of aspergillosis, with mortality exceeding 90%.
Voriconazole can be used due to good CNS penetration [12]. A retro-
spective study showed that in cases of cerebral aspergillosis treated
with voriconazole 35% had a complete or partial response, but the
overall survival rate was still 31% [4,11].
The use of combination high-intensity antifungal treatment for the
treatment of invasive Aspergillus infection has not been extensively
studied. Voriconazole remains ﬁrst-line therapy for Aspergillus infec-
tions but when infections prove refractory, antifungals from diﬀerent
classes can be added or can replace the initial regimen. Likewise, the
management of invasive tracheobronchial aspergillosis primarily en-
tails the use of systemic antifungal therapy. Adjunctive treatment
measures can include inhaled amphotericin and bronchoscopic debri-
dement in select cases [14].
This case illustrates a number of interesting features of Aspergillus
Fig. 4. CT Chest on HD11. Left: coronal. Right: axial. Showing new large areas of cavitation bilaterally with some surrounding groundglass halos, consistent with
necrotizing pneumonia, possibly invasive aspergillus.
Fig. 5. Brain MRI on HD 20. Left: thalamic lesion. Right: frontal lobe lesion.
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infections. It can be challenging to diagnose early, especially in patients
who do not have traditional immunosuppressive risk factors. The lack
of speciﬁc symptoms and early radiological ﬁndings also make the di-
agnosis of invasive infection diﬃcult. Radiographically it can be chal-
lenging to distinguish between early pulmonary Aspergillus and bac-
terial pneumonia, especially if the patient has not had prior cavitary
lesions and is not showing classic radiological signs of Aspergillus.
Tracheobronchial involvement can be seen in post-inﬂuenza invasive
aspergillosis and should be recognized at bronchoscopy which may be
critical for early diagnosis. Most importantly, early diagnosis and in-
itiation of treatment remain critical to limit progression of disease and
improve the survivability of invasive aspergillosis.
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